Publicaciones en las que colabora con A. Gorostidi Pagola (44)

2023

  1. Corrigendum: Clinical and genetic analysis of Costa Rican patients with Parkinson's disease (Front. Neurol., (2022), 12, 656342, 10.3389/fneur.2021.656342)

    Frontiers in Neurology

2022

  1. Endothelial NO synthase 786T/T polymorphism increases hemorrhagic transformation after endovascular thrombectomy

    Nitric Oxide - Biology and Chemistry, Vol. 129, pp. 8-15

2021

  1. A More Homogeneous Phenotype in Parkinson's Disease Related to R1441G Mutation in the LRRK2 Gene

    Frontiers in Neurology, Vol. 12

  2. Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease

    Frontiers in Neurology, Vol. 12

  3. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils

    Acta Neuropathologica, Vol. 142, Núm. 3, pp. 475-494

2019

  1. The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight

    Movement Disorders, Vol. 34, Núm. 12, pp. 1851-1863

  2. Using global team science to identify genetic parkinson's disease worldwide

    Annals of Neurology

2018

  1. LRP10 in α-synucleinopathies

    The Lancet Neurology

  2. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study

    Movement Disorders, Vol. 33, Núm. 11, pp. 1809-1813

2017

  1. Progressive changes in non-coding RNA profile in leucocytes with age

    Aging, Vol. 9, Núm. 4, pp. 1202-1218

  2. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study

    Movement Disorders, Vol. 32, Núm. 7, pp. 1066-1073

  3. The unexpected co-occurrence of GRN and MAPT p.A152T in Basque families: Clinical and pathological characteristics

    PLoS ONE, Vol. 12, Núm. 6

2016

  1. Assessing the role of TUBA4A gene in frontotemporal degeneration

    Neurobiology of Aging, Vol. 38, pp. 215.e13-215.e14

  2. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2R1441G Parkinson's disease

    Movement Disorders, Vol. 31, Núm. 3, pp. 335-343

  3. Genetic Mutation Analysis of Parkinson’s Disease Patients Using Multigene Next-Generation Sequencing Panels

    Molecular Diagnosis and Therapy, Vol. 20, Núm. 5, pp. 481-491

  4. Mutations in LRRK2 impair NF-ΚB pathway in iPSC-derived neurons

    Journal of Neuroinflammation, Vol. 13, Núm. 1

2015

  1. Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain

    Brain

  2. GIGYF2 mutation in late-onset Parkinson's disease with cognitive impairment

    Journal of Human Genetics, Vol. 60, Núm. 10, pp. 637-640

  3. MAPT H1 haplotype is associated with late-onset Alzheimer's disease risk in APOE ε 4 noncarriers: Results from the dementia genetics Spanish consortium

    Journal of Alzheimer's Disease, Vol. 49, Núm. 2, pp. 343-352

  4. SCN4A pore mutation pathogenetically contributes to autosomal dominant essential tremor and may increase susceptibility to epilepsy

    Human Molecular Genetics, Vol. 24, Núm. 24, pp. 7111-7120